Skip to main content

Generic Invega Sustenna Availability

Last updated on Oct 6, 2021.

See also: Generic Invega, Generic Invega Hafyera, Generic Invega Trinza

Invega Sustenna is a brand name of paliperidone, approved by the FDA in the following formulation(s):

INVEGA SUSTENNA (paliperidone palmitate - suspension, extended release;intramuscular)

  • Manufacturer: JANSSEN PHARMS
    Approval date: July 31, 2009
    Strength(s): 39MG/0.25ML (39MG/0.25ML) [RLD] [AB], 78MG/0.5ML (78MG/0.5ML) [RLD] [AB], 117MG/0.75ML (117MG/0.75ML) [RLD] [AB], 156MG/ML (156MG/ML) [RLD] [AB], 234MG/1.5ML (156MG/ML) [RLD] [AB]

Has a generic version of Invega Sustenna been approved?

A generic version of Invega Sustenna has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Invega Sustenna and have been approved by the FDA:

paliperidone palmitate suspension, extended release;intramuscular

  • Manufacturer: TEVA PHARMS USA
    Approval date: July 6, 2021
    Strength(s): 39MG/0.25ML (39MG/0.25ML) [AB], 78MG/0.5ML (78MG/0.5ML) [AB], 117MG/0.75ML (117MG/0.75ML) [AB], 156MG/ML (156MG/ML) [AB], 234MG/1.5ML (156MG/ML) [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invega Sustenna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dosing regimen associated with long acting injectable paliperidone esters
    Patent 9,439,906
    Issued: September 13, 2016
    Assignee(s): Janssen Pharmaceutica NV

    The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

    Patent expiration dates:

    • January 26, 2031
      ✓ 
      Patent use: TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
    • January 26, 2031
      ✓ 
      Patent use: TREATMENT OF SCHIZOPHRENIA
    • January 26, 2031
      ✓ 
      Patent use: DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
    • January 26, 2031
      ✓ 
      Patent use: DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.